Live Analyst Rating Changes 23245 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Martin Fan
WEDB

Martin Fan

Wedbush
Wall Street Analyst
★★★★★
#11
on 13Foresight · ranked by our own returns
86%
Success Rate
+43.0%
Average Return
18 of 21 calls profitable · +37.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 86% of Martin Fan's ratings turned a profit when each position was held for 1 year — averaging +43.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

35 Buy 7 Hold 4 Sell
Martin's Stock Coverage 14 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
IMA
ImageneBio
 Aug 06, 2026 SELL Buy
+199.0% avg upside
12 analysts
$2.00
65.06% Downside
 +0.4% ·
TRAX
First Tracks Biotherapeutics Inc
 Jul 28, 2026 BUY Strong Buy
+6.8% avg upside
8 analysts
$60.00
25.17% Upside
 +8.3% ·
RNAC
Cartesian Therapeutics
 Jun 10, 2026 BUY Strong Buy
+268.0% avg upside
19 analysts
$38.00
333.81% Upside
 +19.1% ·
ARTV
Artiva Biotherapeutics, Inc.
 May 21, 2026 BUY Strong Buy
+159.7% avg upside
7 analysts
$40.00
256.48% Upside
 +47.4% ·
FATE
Fate Therapeutics
 May 14, 2026 BUY Buy
+340.0% avg upside
31 analysts
$7.00
153.64% Upside
 +45.3% ·
VOR
Vor Biopharma
 May 14, 2026 HOLD Buy
+85.5% avg upside
17 analysts
$18.00
23.03% Downside
 +55.1% ·
SANA
Sana Biotechnology
 May 13, 2026 BUY Strong Buy
+168.9% avg upside
14 analysts
$7.00
93.97% Upside
 +12.8% ·
NKTR
Nektar Therapeutics
 May 11, 2026 HOLD Buy
-0.4% avg upside
26 analysts
$80.00
6.93% Upside
 -2.9% ·
ZURA
Zura Bio
 May 08, 2026 BUY Strong Buy
+160.2% avg upside
13 analysts
$15.00
166.50% Upside
 +17.5% ·
ACRS
Aclaris Therapeutics
 May 08, 2026 BUY Strong Buy
+69.0% avg upside
15 analysts
$10.00
69.53% Upside
 +20.1% ·
IMAX
IMAX
 Feb 26, 2026 BUY Strong Buy
-22.5% avg upside
22 analysts
$46.00
10.09% Downside
 +22.6% ·
ORKA
Oruka Therapeutics
 Jan 13, 2026 BUY Strong Buy
+20.5% avg upside
16 analysts
$45.00
57.24% Downside
 +109.2% ·
ZBIO
Zenas BioPharma, Inc.
 Dec 22, 2025 BUY Strong Buy
+32.0% avg upside
11 analysts
$45.00
40.59% Upside
 -44.5% ·
ANAB
AnaptysBio
 Aug 07, 2025 BUY Strong Buy
+26.8% avg upside
26 analysts
$45.00
18.93% Downside
 +316.9% ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Martin Fan — Frequently Asked Questions
How accurate are Martin Fan's stock ratings?
Based on the calls 13Foresight could measure, about 86% of Martin's ratings were profitable over a one-year hold, with an average return of +43.0% per rating, or +37.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Martin ranked on 13Foresight?
Martin Fan is currently ranked #11 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Martin cover?
Martin most recently has ratings on IMA, TRAX, RNAC, ARTV, FATE, VOR, SANA, NKTR, ZURA, ACRS, IMAX, ORKA and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.